Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 4
1(25.0%)
Phase 2
1(25.0%)
4Total
Phase 1(2)
Phase 4(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06491160Completed

Performance and FMRI BOLD Signal Changes in Impulsive Patients

Role: collaborator

NCT05347199Phase 1Completed

Effects of a Single Dose of Amisulpride on Functional Brain Changes

Role: collaborator

NCT04750759Phase 2Terminated

Safety and Preliminary Efficacy of the Combination of Niclosamide and Camostat

Role: lead

NCT04644705Phase 1Completed

Safety and Pharmacokinetics of a Novel Niclosamide Solution in Combination With Camostat

Role: lead

NCT01082302Phase 4Completed

Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage

Role: collaborator

All 5 trials loaded